Thrombomodulin and colorectal cancer
Author Information
Author(s): Hanly A M, Redmond M, Winter D C, Brophy S, Deasy J M, Bouchier-Hayes D J, Kay E W
Primary Institution: Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
Hypothesis
Does thrombomodulin expression correlate with tumor stage and survival in colorectal carcinoma?
Conclusion
Loss of thrombomodulin expression is a key indicator of poor prognosis in colorectal cancer.
Supporting Evidence
- Thrombomodulin expression was found in 26.5% of tumors.
- Patients with positive thrombomodulin expression had a 5-year survival rate of 71%.
- Negative thrombomodulin expression correlated with advanced tumor stage and poor differentiation.
Takeaway
Thrombomodulin helps protect against cancer, and if it's missing, patients may not do as well.
Methodology
Immunostaining of thrombomodulin was performed on tissue sections from 200 colorectal cancer patients, and clinical data were analyzed.
Limitations
The study excluded patients with metastasis or preoperative treatment, which may limit generalizability.
Participant Demographics
Median age was 69 years, with 66.5% male and 33.5% female participants.
Statistical Information
P-Value
P<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website